Disease Domain | Count |
---|---|
Neoplasms | 3 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 2 |
Chemical drugs | 1 |
Target |
Mechanism AIMP2 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism HIF-1α inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 May 2024 |
Sponsor / Collaborator Samsung Medical Center [+21] |
Start Date01 Jul 2023 |
Sponsor / Collaborator |
Start Date13 Dec 2022 |
Sponsor / Collaborator Asan Medical Center [+10] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
DGG200064 | Colonic Cancer More | Preclinical |
Bcl-848 ( AIMP2 ) | Neoplasms More | Preclinical |
LW-1564 ( HIF-1α ) | Neoplasms More | Preclinical |